Kite Pharma (KITE): Zuma-1 Debate Not Significant - Jefferies
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after a debate over pot'l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics occurred around the word "relapsed".
The analyst believes little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed patients are healthier than refractory patients. Analysis suggests otherwise and we think FDA should come to a similar conclusion.
No change to the price target of $72.
Shares of Kite Pharma closed at $51.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Alcobra Ltd. (ADHD) to Hold
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
- Deutsche Bank Raises Price Target on IHS Markit (INFO) to $44; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!